1Eck MJ, Yun CH. Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer[J]. Bioehim Biophys Acta, 2011, 1804(3):559-566.
2Suda K, Murakami I, Katayama T,et al. Reciprocal and comple- mentary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer[J]. Clin Cancer Res,2010,16(22):5489-5498.
3Yun CH, Mengwasser KE, Toms AV,et al. The T790M muta- tion in EGFR kinase causes drug resistance by increasing the af- finity for ATP[J]. Proc Natl Acad Sci USA, 2008,105 (6) : 2070- 2075.
4Giaccone G, Wang Y. Strategies for overcoming resistance to EG- FR family tyrosine kinase inhibitors[J]. Cancer Treat Rev, 2011, 37(6) :456-464.
5Zhou W, Ercan D, Jnne PA,etal. Discovery of selective irrevers- ible inhibitors for EGFR-T790M[J]. Bioorg Med Chem Lett, 2011,21(2) :638-643.
